Held by 6 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $39.2M Position in Alkermes Avoro's entry into ALKS likely reflects conviction in the company's late-stage pipeline, particularly ALKS 5461 (buprenorphine/samidorphan) for major depressive disorder, which achieved primary endpoints in Phase 3 and faces potential FDA decision in 2024.
AI analyst context — unlock full analysis
**Signal Note: Baker Bros. Initiates Major Position in Alkermes (ALKS)** **Note: The reported position value of ~$280B appears to be a data error — based on 10M shares and ALKS's recent price (~$28-$32/share), the actual position is likely ~$280-320M, which would still represent a significant concentrated bet.** Baker Bros. building a new position of this magnitude in ALKS is notable given their track record of high-conviction biotech bets; the likely thesis centers on the continued commercial ramp of Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar I disorder, which has been on a strong growth trajectory with quarterly revenues accelerating, plus the durable cash flows from Vivitrol (opioid dependence) and their royalty stream from Biogen on Vumerity (
+ 4 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial